Lagios MD and Silverstein MJ. 2010.Ductal carcinoma in situ: dilemma or denouement. J Clin Oncol, 28: 218-219.

​

Silverstein MJ and Lagios MD. 2010. Choosing treatment for patients with ductal carcinoma in situ (DCIS): Fine tuning the University of Southern California/Van Nuys Prognostic Index (USC/VNPI). J Nat Can Instit Mono, 41: 193-196.

​

Wehner P, Lagios MD and Silverstein MJ. 2013.  DCIS treated with excision alone using the National Comprehensive Cancer Network (NCCN) Guidelines. Ann Surg Oncol, 20: 3175-3175.

​

Silverstein MJ and Lagios MD. 2013. Postmastectomy irradiation for DCIS with narrow margins; not for the Festrunk Brothers. Ann Surg Oncol 20: 4057-4058.

​

Lagios MD and Silverstein MJ. 2014. Risk of recurrence of ductal carcinoma in situ by Oncotype DX technology: some concerns. Cancer, 120: 1085.

​

Silverstein MJ, Lagios MD. 2015. Treatment of patients with ductal carcinoma in situ (DCIS) of the breast using the University of Southern California/Van Nuys (USCV/VNPI) Prognostic Index. Breast J, 21(2): 127-132.

​

Lagios MD and Silverstein MJ. 2015. Ductal carcinoma in situ: Recent history and areas of controversy. Breast J, 21(1): 21-26.

​

Silverstein MJ and Lagios MD. 2015. Treatment selection for patients with ductal carcinoma in situ (DCIS) of the breast using the University of Southern California/Van Nuys (UCS/VNPI) Prognostic Index. Breast J, 21(2): 127-132.

​

Lagios MD. 2015. The impact of Ki-67 on immunostaining in classification of luminal subtypes of breast cancer. Breast J, 21: 463-464.

​

Lin K, Lagios MD, Silverstein MJ. 2016. Dangers of excluding margin status from a ductal carcinoma in situ prognostic score. J Clin Oncol, 34: 3484-3485.

​

Khan S, Epstein M, Lagios MD, Silverstein MJ. 2017. Are we overtreating ductal carcinoma in situ (DCIS)? Annals of Surg Oncol, 24: 59-63.

​

Dr. Lagios’ Complete Publications List

​